Unfortunately, a significant number of patients die between each line of therapy, highlighting the need to use treatments that offer a meaningful survival benefit as soon as their indication allows.1
IT'S IMPORTANT TO CHOOSE AN OPTION IN THIRD-LINE mBC THAT GIVES MORE PATIENTS AN OPPORTUNITY FOR AN OS BENEFIT1
Neutropenia: Severe neutropenia (ANC <500/mm3) lasting >1 week occurred in 12% of patients with mBC and liposarcoma or leiomyosarcoma. Febrile neutropenia occurred in 5% of patients with mBC and 2 patients (0.4%) died from complications. Febrile neutropenia occurred in 0.9% of patients with liposarcoma or leiomyosarcoma, and fatal neutropenic sepsis occurred in 0.9% of patients. Patients with mBC with elevated liver enzymes >3 × ULN and bilirubin >1.5 × ULN experienced a higher incidence of Grade 4 neutropenia and febrile neutropenia than patients with normal levels. Monitor complete blood cell counts prior to each dose, and increase the frequency of monitoring in patients who develop Grade 3 or 4 cytopenias. Delay administration and reduce subsequent doses in patients who experience febrile neutropenia or Grade 4 neutropenia lasting >7 days.
References: 1. Kantar Health. Treatment architecture: Western Europe breast cancer. CancerMPact® Western Europe, 2017. 2. Decision Resources Group. Burlington, MA. Report generated January 2017.